A retrospective multicenter study validating predictive biomarkers of Ipilimumab treatment in metastatic melanoma patients.

Trial Profile

A retrospective multicenter study validating predictive biomarkers of Ipilimumab treatment in metastatic melanoma patients.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms CARAMEL
  • Most Recent Events

    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
    • 26 Jul 2016 New trial record
    • 07 Jun 2016 Interim results (n=70) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top